Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | TTK | P33981 | 2/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.32 |
| ▸ | USP1 | O94782 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30278827 | 1.00 | FGFR4 (0.38) | FGFR4PIM1TTKPIM2MEN1 | |
| SCHEMBL3967401 | 0.81 | FGFR4 (0.48) | FGFR4PIM1TTKPIM2MEN1 | |
| SCHEMBL31139435 | 0.81 | FGFR4 (0.48) | FGFR4PIM1TTKPIM2MEN1 | |
| SCHEMBL25538721 | 0.80 | FGFR4 (0.36) | FGFR4PIM1TTKPIM2MEN1 | |
| SCHEMBL17807803 | 0.80 | USP1 (0.34) | USP1 | |
| SCHEMBL22419389 | 0.78 | MEN1 (0.38) | FGFR4PIM1TTKPIM2MEN1 | |
| SCHEMBL18459263 | 0.78 | IDH1 (0.40) | FGFR4PIM1TTKPIM2MEN1 | |
| SCHEMBL24170655 | 0.77 | FGFR4 (0.47) | FGFR4PIM1TTKPIM2MEN1 | |
| SCHEMBL25538733 | 0.77 | MEN1 (0.38) | FGFR4PIM1TTKPIM2MEN1 | |
| SCHEMBL25538717 | 0.76 | FGFR4 (0.39) | FGFR4PIM1TTKPIM2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559505-B2 | IDH mutant inhibitor and use thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2026-02-24 | — | — | US | disclosed |
| US-20230174550-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-06-08 | — | — | US | disclosed |
| US-20230174550-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-06-08 | — | — | US | disclosed |
| US-20230174550-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-06-08 | — | — | US | disclosed |
| CN-115768775-A | IDH mutant inhibitor and application thereof | 微境生物医药科技(上海)有限公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-113845528-A | IDH mutant inhibitor and application thereof | 微境生物医药科技(上海)有限公司 | 2021-12-28 | — | — | CN | disclosed |
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1080092-B1 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | DOBRUSIN ELLEN MYRA (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | CCNI, CCNH, CCNA1 | FGFR4 95/4885PIM1 1189/4885TTK 339/4885 |
| US-12559505-B2 | IDH mutant inhibitor and use thereof | IDH3A, IDH1, IDH3B | FGFR4 820/4885PIM1 292/4885TTK 1382/4885 |
| US-20230174550-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | IDH1, IDH3A, IDH3B | FGFR4 536/4885PIM1 404/4885TTK 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.